Aims & Scope

Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies.

The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology.

Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor.

Leukemia & Lymphoma is also dedicated to education in the form of reviews, commentaries, conference summaries and emerging drug profiles.

All submissions are subject to peer review and disclosure requirements, as stipulated by the International Committee of Medical Journal Editors (ICMJE).

Rapid turnaround time for reviews as well as fast online publication assure timely access to accepted publications.

The journal provides a premier reference source for physicians and scientists interested in clinical, translational, and laboratory research, as well as clinical diagnosis and treatment of patients with malignant hematological disorders.

View Aims & Scope

Metrics & Ranking

Impact Factor

Year Value
2025 2.2
2024 2.20

SJR (SCImago Journal Rank)

Year Value
2024 0.778

Quartile

Year Value
2024 Q2

h-index

Year Value
2024 105

Journal Rank

Year Value
2024 7048

Journal Citation Indicator

Year Value
2024 1941

Impact Factor Trend


Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.


Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.


Quick Facts

Current Factor
2.2
First Published: 2025

SJR (SCImago Journal Rank)

SJR
0.778
First Published: 2024

Quartile

Current Quartile
Q2
First Published: 2024

Similar Journals

Top Journals in Related Fields